Kai Chen
机构:Center for Drug Evaluation and Research, Nanjing Tech University, Shandong University of Traditional Chinese Medicine, Johns Hopkins University, Sun Yat-sen University, Guangxi Medical University, Bengbu Medical College, Chinese Center For Disease Control and Prevention, Jilin University, Chinese Academy of Medical Sciences & Peking Union Medical College, Wenzhou Medical University, Columbia University Irving Medical Center, Novant Health, Guangzhou University, Soochow University, Meizhou City People's Hospital, Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Guangzhou Women and Children Medical Center, Chinese Academy of Medical Sciences Dermatology Hospital, First Affiliated Hospital of Guangdong Pharmaceutical University, First Affiliated Hospital of GuangXi Medical University, Drug Discovery Laboratory (Norway), Mayo Clinic in Florida, Sun Yat-sen University Cancer Center, First Affiliated Hospital of Soochow University, Shandong Academy of Pharmaceutical Sciences, Shanghai Children's Hospital, Pharmaceutical Biotechnology (Czechia), Sidney Kimmel Comprehensive Cancer Center, State Key Laboratory of Materials-Oriented Chemical Engineering, Hangzhou Dianzi University, The University of Texas Health Science Center at Houston, Guangzhou Medical University · ORCID:0000-0002-8647-1182
发表论文 633 篇 · 总被引 21735 次 · h-index 70
代表论文
- Sesamin promotes the survival of skin flaps in rats by inhibiting ferroptosis through the Nrf2/SLC7A11/GPX4 signaling pathway (2025 · Journal of Ethnopharmacology · 被引 3)
- Degradation of IRF6 by TRIM59 in tumor cells triggers PGM1-mediated glycolysis to regulate cell proliferation in neuroblastoma (2025 · Cell Death and Disease · 被引 3)
- Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival (2025 · Translational Cancer Research · 被引 3)
- Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS) (2025 · Cancer Research · 被引 3)
- Angiogenesis-osteogenesis coupling lithium-loaded bioglass/GelMA hydrogel for bone regeneration (2025 · Biomaterials Advances · 被引 2)
- One-Shot Rational Design of Covalent Drugs with CovalentLab (2025 · JACS Au · 被引 2)